A son of glembatumumab vedotin has just started its phase 1 study.
ApexOnco Front Page
Recent articles
Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
A first-in-human trial of PRT12396 starts next month.
Early data are coming with the KRAS G12D degrader ARV-806.
Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
After reporting stellar data at ASH, Terns is acquired for $6.7bn.
Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
